AbbVie Inc. (NYSE:ABBV) reported fourth-quarter 2025 sales of $16.62 billion on Wednesday, beating the consensus of $16.42 billion.

Sales increased 10% on a reported basis or 9.5% on an operational basis. The company reported adjusted earnings of $2.71 per share, up 25.5%, beating the consensus of $2.65.

Global net revenues from the immunology portfolio were $8.63 billion, up 18.3% (+17.7% on an operational basis), including Skyrizi sales increased 32.5% to $5.01 billion; Rinvoq sales reached $2.37 billion, an increase of 29.5%; and Humira sales fell 25.9% to $1.25 billion.

Neuroscience portfolio sales were $2.96 billion, up 17.9%; Vraylar net revenues were $1.02 billion, up 10.5%; and Botox Therapeutics' net revenues were $991 million, up 13.4%.

Oncology portfolio generated sales of $1.66 billion, down 1.5%, including Imbruvica's net revenues of $671 million, down 20.8%; Venclexta's revenues were $711 million, up 8.6%; and Elahere's revenues were $182 million.

Global Botox Cosmetic net revenues were $717 million, up 4.2%, and Juvederm net revenues were $249 million, a decrease of 10.7%.

The adjusted gross margin ratio was 83.6%.

Guidance

AbbVie issued its fiscal 2026 adjusted earnings of $14.37-$14.57 per share versus the consensus of $14.24.

Analyst Take

Citing a BMO Markets analyst, Bloomberg highlighted that investors might see AbbVie's results as "somewhat lower quality" as it was driven by a Humira beat, which continues to erode. He added that while aesthetics showed signs of improvement, "filler softness" remains a challenge.

ABBV Price Action: AbbVie shares were down 6.70% at $210.53 at the time of publication on Wednesday, according to Benzinga Pro data.

Photo via Shutterstock